HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin&5-fluorouracil was effective
in unresectable hepatocellular carcinoma (HCC). The program of FOLFOX-HAIC in HCC was
performed for 1 day (HAIC 1d) or 2 days (HAIC 2d). We hereby retrospectively compared the
efficacy and safety between these two treatment regimens, and explored the predictive power
of thymidylate synthase (TYMS), an enzyme involved in the DNA synthesis process and
metabolism of fluorouracil. Patients with HCC staged BCLC A-B receive HAIC only, and patients
with HCC staged BCLC C receive HAIC plus systemic treatment, such as sorafenib, A+T,
lenvatinib.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
First People's Hospital of Foshan Guangzhou No.12 People's Hospital